AFID Therapeutics

AFID Therapeutics is a biotechnology company specializing in the development of carbohydrate-based small molecule therapeutics. The company leverages its proprietary chemistry platform to create novel glycomimetics and complex carbohydrates for treating infectious diseases, cancer, and metabolic disorders. AFID's lead programs include next-generation neuraminidase inhibitors for influenza and innovative treatments for various solid tumors. By focusing on the critical role of glycobiology in disease progression, the company aims to provide high-potency, low-toxicity alternatives to current standard-of-care treatments. The firm utilizes its Advanced Functionalized Intermediates for Drug Discovery technology to streamline the synthesis of complex sugar molecules. Based in Michigan, the company maintains strong academic ties and has been supported by various federal research grants.